The Best Blood Marker Depends on When You Look

Summary

Seventeen years of samples found amyloid-beta misfolding predicted future dementia earlier than plasma p-tau217.

Why it matters

Seventeen years of samples found amyloid-beta misfolding predicted future dementia earlier than plasma p-tau217.

Limits and context

• Plasma p-tau217 performed strongly once Alzheimer disease was clinically manifest but only moderately before symptoms, while a marker of amyloid-beta protein misfolding showed stronger preclinical prediction and improved further in a combined panel.
• The observational EMBO Molecular Medicine study informs screening research; it does not by itself establish a population test, treatment decision or certain diagnosis for an individual.

Key claims

1. Seventeen years of samples found amyloid-beta misfolding predicted future dementia earlier than plasma p-tau217.

   Qualification: Plasma p-tau217 performed strongly once Alzheimer disease was clinically manifest but only moderately before symptoms, while a marker of amyloid-beta protein misfolding showed stronger preclinical prediction and improved further in a combined panel.

   Evidence: source-2026-07-28-010

Sources

1. Ruhr University Bochum via EurekAlert: Alzheimer blood biomarkers across disease stagesRuhr University Bochum via EurekAlert · official announcement

Corrections

No corrections have been recorded for this story.